Ribociclib + Fulvestrant: Quality of Life Analysis
Strategic analysis of Patient-Reported Outcomes (PROs) from the MONALEESA-3 Phase III trial.
0.81
HR for Global Health TTD
+5.6 mo
Delay in Pain Deterioration
0.76
HR Emotional Functioning
N=726
Total Population
"Adding ribociclib to fulvestrant maintains HRQOL while significantly prolonging progression-free survival. A consistent trend favoring ribociclib was observed across functional and symptom scales."
Study Design & Population
Randomized, double-blind, placebo-controlled Phase III trial in HR+/HER2- advanced breast cancer.
Hazard Ratios: Time to Definitive Deterioration (TTD)
Hazard Ratios < 1.0 indicate a favorable delay in deterioration for the Ribociclib arm.
Median Months to Deterioration (Absolute Benefit)
Ribociclib + Fulvestrant consistently extends the time before quality of life deteriorates.
Baseline Global Health Status
Baseline scores were well balanced between treatment groups (Score 0-100).
Pain Severity Index (BPI-SF)
Significant delay in pain deterioration (42.7 vs 35.9 months).
Risk Reduction Overview
Relative risk reduction (1 - HR) across all measured domains.
Data Appendix
| Metric | Ribociclib + Fulv | Placebo + Fulv | HR (95% CI) | Source |
|---|
Source:
DOI:
DOI: